Authors will follow up PACE-B with PACE-C, a study supported with additional funding from The Royal Marsden Cancer Charity. This will compare patients receiving SBRT and androgen deprivation therapy (ADT - an anti-hormone therapy), with ADT, Image-Guided and Intensity Modulated radiotherapy.
The PACE-B study was funded by Accuray, sponsored by The Royal Marsden NHS Foundation Trust, co-ordinated by the Clinical Trials and Statistics Unit at The Institute of Cancer Research (ICR) and endorsed by Cancer Research UK.
Ad Statistics
Times Displayed: 64511
Times Visited: 2110 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
Notes to Editors
For further information please contact Hannah Bransden, Senior PR & Communications Officer at The Royal Marsden on Hannah.bransden@rmh.nhs.uk or 020 7811 8244
'Intensity Modulated Fractionated Radiotherapy Versus Stereotactic Body Radiotherapy for Prostate Cancer (PACE-B): Acute Toxicity Results From a Randomised Open-label Phase III Non-inferiority Trial' is published today Tuesday 17 September 2019 at 23:30 UK BST in The Lancet Oncology. It will be available here once published: http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30569-8/fulltext
* The PACE-B trial is an international multi-centre randomised controlled trial with patients from the United Kingdom, Ireland and Canada.
* The control arm - CFMHRT - was initially 39 doses over seven/eight weeks. The trial protocol was amended following the publication of data from the CHHiP trial, changing the dose to 20 over four weeks. Centres were required to choose either the original or new protocol for all subsequent patients.
* Radiotherapy in each centre was delivered either by a CyberKnife treatment platform or conventional linear accelerators (LINACs).
* The Royal Marsden was one of the first London NHS Trusts to install the latest model of CyberKnife in 2011.
* The platform has x-ray cameras that monitor the position of the tumour and sensors that monitor the patient's breathing. This enables the robot to reposition the radiotherapy bean during treatment to track a moving tumour.
* The CyberKnife at The Royal Marsden was funded by The Royal Marsden Cancer Charity.
About The Royal Marsden NHS Foundation Trust
The Royal Marsden opened its doors in 1851 as the world's first hospital dedicated to cancer diagnosis, treatment, research and education.
Today, together with its academic partner, The Institute of Cancer Research (ICR), it is the largest and most comprehensive cancer centre in Europe seeing and treating over 55,000 NHS and private patients every year. It is a centre of excellence with an international reputation for ground-breaking research and pioneering the very latest in cancer treatments and technologies.
